NDC product
Sumatriptan and Naproxen Sodium
NDC 65862-928 · Aurobindo Pharma Limited
Key facts
| Product NDC | 65862-928 |
|---|---|
| Proprietary name | Sumatriptan and Naproxen Sodium |
| Nonproprietary name | Sumatriptan and Naproxen Sodium |
| Substances | SUMATRIPTAN SUCCINATE, NAPROXEN SODIUM |
| Dosage form | TABLET, FILM COATED |
| Route | ORAL |
| Labeler | Aurobindo Pharma Limited |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA207457 |
| Pharmacologic classes | Anti-Inflammatory Agents, Non-Steroidal [CS], Cyclooxygenase Inhibitors [MoA], Nonsteroidal Anti-inflammatory Drug [EPC], Serotonin 1b Receptor Agonists [MoA], Serotonin 1d Receptor Agonists [MoA] and 1 more |
| Marketing start | Feb 15, 2018 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: